Studies of the expression of encogenes and superoxide dismutase (SOD) in human malignant brain tumors.

我们报道了人类脑肿瘤组织中自由基、过氧化氢酶和超氧化物歧化酶（SOD）的数据，并在更大体积的脑肿瘤组织中再次进行了测量。然而，这些数据并没有显示恶性肿瘤和良性肿瘤之间的差异，也没有显示脑肿瘤患者的预后。最近，我们发表了从一位年轻女性身上获得的胶质母细胞瘤细胞培养。现在我们正在研究在体外给药抗癌剂和/或照射培养细胞后，细胞培养基中SOD的表达。免疫组化技术检测了SOD在人类恶性脑肿瘤如间变性星形细胞瘤、胶质母细胞瘤、髓母细胞瘤和转移瘤中的表达，以及在脑膜瘤、垂体腺瘤和神经鞘瘤等良性脑肿瘤中的表达。总的来说，恶性脑肿瘤中SOD的表达低于良性肿瘤。然而，恶性脑肿瘤中SOD的高表达仅在复发病例中观察到。因此，恶性脑肿瘤患者预后不良，可能与SOD免疫染色阳性无关，这与SOD的生物学行为有关。以恶性脑肿瘤为重点，SOD免疫染色阳性越低预后越好，阳性越高预后越差。因此，恶性脑肿瘤中SOD的测定是评估患者预后的一个很好的指标。另一方面，良性脑肿瘤患者的预后与肿瘤切除程度的关系大于与肿瘤组织中SOD的阳性程度的关系。恶性脑肿瘤对辅助治疗的耐药是由于化疗和/或放疗不充分或不完全。我们下一步的研究将集中在这一点上，并将能够制定有效的治疗策略，以防止辅助治疗中的耐药。

We have reported the data of free radical, catalase and superoxide dismutase (SOD) in human brain tumors, and we measured them again in much more volume of brain tumor tissues. However, the data did not indicate the difference between malignant and benign tumors or the prognosis of the patients with brain tumor.Recently, we published the cell culture of glioblastoma which obtain from a young female. Now weare studying to see the expression of SOD in the cell culture medium following the administration of anti cancer agents and/or irradiation to the culture cell in invitro.The expression of SOD in human malignant brain tumors such as anaplastic astrocytomas, glioblastomas medulloblastomas and metastatic tumors, and in human benign brain tumors such as meningiomas, pituitary adenomas and schwannomas which done using an immunohistochemical technique. In general, the expression of SOD was lower in malignant brain tumors than benign tumors. However, higher expression of SOD in malignant brain tumors observed only in recurrent cases. Therefore poor outcome of the patients with malignant brain tumor, may not depend on the positivity of SOD immunostain, due to it's biological behavior.A focused in malignant brain tumors, better outcome was observed in lower positivity of SOD immunostain and worse outcome in higher positivity. Thus, the measurement of SOD in malignant brain tumors was a good indicator to asses the prognosis of the patients. On the other hand, the outcome of the patients with benign brain tumors was much correlate to the degree of tumor removal than the positivity of SOD in the tumor tissues.The resistancy of malignant brain tumors to the adjuvant therapies is due to the inadequate or imcomplete chemotherapy and/or radiotherapy. Our next study will be focused to this point and will able to make an effective therapeutic strategy to prevent resistency in the adjuvant therapies.